This is an ophthalmic drug that DWTI in-licensed from a British company in 2015.
We are seeking to develop new drugs by expanding the indications of compounds already on the market to other disease types. The expected benefits of this so-called repositioning approach are relatively low development costs and risks.
|Clinical indication||Ophthalmic treatment agent (non-disclosure)|
|Development process||Phase I clinical trials (Japan)|
|Licensee||ROHTO Pharmaceutical Co., Ltd.|
- 2022.12Phase I clinical trials (Japan) completed
- 2022.03Phase I clinical trials (Japan) started
- 2019.12Licensed out rights of Japan to ROHTO Pharmaceutical Co., Ltd.
- 2015.06In-licensed rights of Japan from British Co.